2U3 Stock Chart & Stats
€62.40
€0.94(1.59%)
At close: 4:00 PM EDT
€62.40
€0.94(1.59%)
Day’s Range― - ―
52-Week Range€52.42 - €74.62
Previous CloseN/A
Volume741.00
Average Volume (3M)4.01K
Market Cap
€28.38B
Enterprise Value€29.78K
Total Cash (Recent Filing)€1.46B
Total Debt (Recent Filing)€5.31B
Price to Earnings (P/E)50.0
Beta0.80
Next Earnings
Nov 10, 2026EPS Estimate
0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.29
Shares Outstanding499,700,000
10 Day Avg. Volume3,208
30 Day Avg. Volume4,011
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€75.87Price Target Upside21.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)3
Revenue Forecast (FY)€9.52B
Bulls Say, Bears Say
Bulls Say
Diversified Recurring Eye-care ModelAlcon's two-segment model combines procedure-linked surgical consumables with repeat contact-lens purchases. That mix supports recurring demand across clinical and retail channels, while its installed equipment base can encourage ongoing compatible consumable, service, and upgrade revenue.
Sustained Revenue Growth And Broad DemandMulti-year revenue expansion indicates durable demand for Alcon's surgical and vision-care offerings rather than reliance on a single quarter. Broad growth across franchises and geographies improves resilience, supports scale, and provides a foundation for continued investment in products and distribution.
Strong Cash Generation And Financial FlexibilityAlcon's substantial and improving free cash flow provides internal funding for research, product launches, commercial investment, and shareholder returns. Strong cash generation also improves resilience when operating conditions fluctuate, allowing the company to pursue growth without depending as heavily on external financing.
Bears Say
Recent Profitability And Return CompressionThe recent decline in net margin and return on equity indicates that revenue growth is not currently translating into earnings as efficiently as in prior periods. If operating-cost or pricing pressure persists, weaker profitability could constrain reinvestment capacity and reduce the benefit of scale.
R&D Setback From PowerVision DiscontinuationEnding the PowerVision accommodating-IOL programs removes a potential long-term product pathway and represents a setback for the surgical innovation pipeline. It also means development resources and expected future commercial optionality from that program will not contribute to growth.
Competitive And Adoption Pressure In Implantables And GlaucomaSlow implantables growth and limited Hydrus adoption show that competition, reimbursement dynamics, and physician uptake can restrain key surgical franchises. Persistent pressure in these areas could weaken portfolio growth and require greater investment to defend share or accelerate adoption.
Alcon News
2U3 FAQ
What was Alcon Inc’s price range in the past 12 months?
Alcon Inc lowest stock price was €52.42 and its highest was €74.62 in the past 12 months.
What is Alcon Inc’s market cap?
Alcon Inc’s market cap is €28.38B.
When is Alcon Inc’s upcoming earnings report date?
Alcon Inc’s upcoming earnings report date is Nov 10, 2026 which is in 50 days.
How were Alcon Inc’s earnings last quarter?
Alcon Inc released its earnings results on Aug 10, 2026. The company reported €0.721 earnings per share for the quarter, beating the consensus estimate of €0.64 by €0.082.
Is Alcon Inc overvalued?
According to Wall Street analysts Alcon Inc’s price is currently Undervalued.
Does Alcon Inc pay dividends?
Alcon Inc does not currently pay dividends.
What is Alcon Inc’s EPS estimate?
Alcon Inc’s EPS estimate is 0.75.
How many shares outstanding does Alcon Inc have?
Alcon Inc has 499,700,000 shares outstanding.
What happened to Alcon Inc’s price movement after its last earnings report?
Alcon Inc reported an EPS of €0.721 in its last earnings report, beating expectations of €0.64. Following the earnings report the stock price went up 4.293%.
Which hedge fund is a major shareholder of Alcon Inc?
Currently, no hedge funds are holding shares in DE:2U3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€75.87 (21.58% Upside)
€75.87 (21.58% Upside)
Blogger Sentiment
Bullish
DE:2U3 Sentiment 89%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.98%
12-Months-Change
Fundamentals
Return on Equity
0.55%
Trailing 12-Months
Asset Growth
-0.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alcon Inc
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
2U3 Company Deck
2U3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a clearly positive operational and financial quarter: 7% consolidated sales growth, strong equipment performance (UNITY), margin expansion (+250 bps gross margin, +160 bps operating margin), EPS and cash-flow strength, and multiple successful new-product introductions (PanOptix Pro, TRYPTYR, Valeda). Notable negatives included the discontinuation of the PowerVision accommodating IOL program, slower growth in implantables and certain glaucoma products, a few one-time margin items and manufacturability timing for UNITY DX. On balance, the positives — consistent revenue and margin expansion, robust cash generation and multiple high-potential product rollouts and market-share gains — outweigh the setbacks.View all DE:2U3 earnings summaries2U3 Stock 12 Month Forecast
Average Price Target
€75.87
▲(21.58% Upside)
Technical Analysis
Roche Holding AG
―
Straumann Holding AG
―
Siegfried Holding AG
―
Tecan Group AG
―
medmix AG
―